Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies

Chemoimmunotherapy (CIT) and targeted therapy with single‐agent ibrutinib are both recommended first‐line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. Using ibrutinib data from the RESONATE‐2 (PCYC‐1115/1116) study conducted in patients...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Am J Hematol
المؤلفون الرئيسيون: Robak, Tadeusz, Burger, Jan A., Tedeschi, Alessandra, Barr, Paul M., Owen, Carolyn, Bairey, Osnat, Hillmen, Peter, Simpson, David, Grosicki, Sebastian, Devereux, Stephen, McCarthy, Helen, Coutre, Steven E., Quach, Hang, Gaidano, Gianluca, Maslyak, Zvenyslava, Stevens, Don A., Moreno, Carol, Gill, Devinder S., Flinn, Ian W., Gribben, John G., Mokatrin, Ahmad, Cheng, Mei, Styles, Lori, James, Danelle F., Kipps, Thomas J., Ghia, Paolo
التنسيق: Artigo
اللغة:Inglês
منشور في: John Wiley & Sons, Inc. 2018
الموضوعات:
Research Articles
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6221114/
https://ncbi.nlm.nih.gov/pubmed/30129285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25259
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة